
Opinion|Videos|June 11, 2024
PROUD-PV/CONTINUATION-PV Trials for Ropeginterferon Alfa-2b in Polycythemia Vera
This segment discusses the key efficacy and safety considerations from the PROUD-PV and CONTINUATION-PV trials evaluating ropeginterferon alfa-2b as a treatment option for polycythemia vera.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
2
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
3
Beyond SC Daratumumab: Emerging Therapeutic Approaches for Smoldering Myeloma
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5






































